Natixis’s Fulcrum Therapeutics FULC Stock Holding History

Natixis’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250,000	Closed	-$7.11M	–	1276
2021 Q3	$7.11M	Buy	+250,000	New	+$4.74M	0.02%	448

Other funds holding FULC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Natixis's FULC Position: Q4 2021 in Review

Natixis sold out of Fulcrum Therapeutics (FULC) in Q4 2021, closing a stake of 250,000 shares — an estimated $7.11M sold.

Natixis first reported a position in FULC in Q3 2021 and held it in 1 quarter. The position peaked at $7.11M in Q3 2021. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2021.

Natixis reported no remaining Fulcrum Therapeutics position as of Q4 2021 after selling out during the quarter.
Natixis sold 250,000 Fulcrum Therapeutics shares in Q4 2021, an estimated $7.11M.
Natixis first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 1 quarter.
Natixis's Fulcrum Therapeutics position peaked at $7.11M in Q3 2021.
110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2021.

Based on Natixis's 13F filing for Q4 2021, filed 14 Feb 2022.